British Columbia Centre for Disease Control, Vancouver, Canada.
Euro Surveill. 2013 Jan 31;18(5):20394. doi: 10.2807/ese.18.05.20394-en.
The 2012/13 influenza season in Canada has been characterised to date by early and moderately severe activity, dominated (90%) by the A(H3N2) subtype. Vaccine effectiveness (VE) was assessed in January 2013 by Canada's sentinel surveillance network using a test-negative case-control design. Interim adjusted-VE against medically attended laboratory-confirmed influenza A(H3N2) infection was 45% (95% CI: 13-66). Influenza A(H3N2) viruses in Canada are similar to the vaccine, based on haemagglutination inhibition; however, antigenic site mutations are described in the haemagglutinin gene.
截至目前，加拿大 2012/13 年流感季节的特点是发病早且中度严重，主要（90%）由 A(H3N2) 亚型引起。加拿大哨点监测网络于 2013 年 1 月采用病例对照试验设计评估了疫苗有效性（VE）。针对有医疗记录的实验室确诊 A(H3N2) 流感感染的临时调整 VE 为 45%（95%CI：13-66）。根据血凝抑制试验，加拿大的 A(H3N2) 流感病毒与疫苗相似；然而，血凝素基因中描述了抗原表位突变。
